Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Sun Pharma Advanced Research Co's annualized net income for the quarter that ended in Mar. 2026 was ₹70,454 Mil. Sun Pharma Advanced Research Co's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹12,675 Mil. Therefore, Sun Pharma Advanced Research Co's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 555.86%.
The historical rank and industry rank for Sun Pharma Advanced Research Co's Return-on-Tangible-Equity or its related term are showing as below:
NSE:SPARC'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -252.29 Med: -114.98 Max: 802.18
Current: 802.18
During the past 13 years, Sun Pharma Advanced Research Co's highest Return-on-Tangible-Equity was 802.18%. The lowest was -252.29%. And the median was -114.98%.
NSE:SPARC's Return-on-Tangible-Equity is ranked better than 94.54% of 897
companies
in the Drug Manufacturers industry
Industry Median: 7.9
vs NSE:SPARC: 802.18
Sun Pharma Advanced Research Co (NSE:SPARC) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Sun Pharma Advanced Research Co Return-on-Tangible-Equity Related Terms
Sun Pharma Advanced Research Co Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sun Pharma Advanced Research Co Return-on-Tangible-Equity Chart
NSE:SPARC vs ZTS, UTHR: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Sun Pharma Advanced Research Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sun Pharma Advanced Research Co Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sun Pharma Advanced Research Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Sun Pharma Advanced Research Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 555.86% mean?
Sun Pharma Advanced Research Co (NSE:SPARC) has a Return-on-Tangible-Equity of 555.86% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Sun Pharma Advanced Research Co and its competitors. According to the industry distribution chart, Sun Pharma Advanced Research Co ranks #49 out of 897 companies in the Drug Manufacturers industry, placing it in the top 5.5%.
Is Sun Pharma Advanced Research Co's Return-on-Tangible-Equity too high?
Sun Pharma Advanced Research Co's current Return-on-Tangible-Equity is 555.86%. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.90. Sun Pharma Advanced Research Co's value of 555.86% is 6936.2% above this industry median. Based on the distribution chart, Sun Pharma Advanced Research Co ranks #49 out of 897 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sun Pharma Advanced Research Co has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sun Pharma Advanced Research Co's Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sun Pharma Advanced Research Co ranks #49 out of 897 companies for Return-on-Tangible-Equity. This places Sun Pharma Advanced Research Co in the top 6% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 7.90. Sun Pharma Advanced Research Co's value of 555.86% is 6936.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 897 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sun Pharma Advanced Research Co's current Return-on-Tangible-Equity of 555.86% is 6936.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Sun Pharma Advanced Research Co and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sun Pharma Advanced Research Co's current Return-on-Tangible-Equity is 555.86%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sun Pharma Advanced Research Co stock overvalued right now?
Based on GuruFocus' analysis, Sun Pharma Advanced Research Co (NSE:SPARC) is currently considered Possible Value Trap. The stock's GF Value™ is ₹4,514.26, compared to a current price of ₹266.34 — trading 94.1% below its estimated fair value. The current Return-on-Tangible-Equity is 555.86% and 6936.2% above the Drug Manufacturers industry median of 7.90. Sun Pharma Advanced Research Co's overall GF Score™ is 67/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Sun Pharma Advanced Research Co (NSE:SPARC), the current Return-on-Tangible-Equity is 555.86% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sun Pharma Advanced Research Co (NSE:SPARC) Overvalued in 2026?
Based on GuruFocus' analysis, Sun Pharma Advanced Research Co stock appears to be undervalued.
The current stock price of ₹266.34 is trading 94.1% below its estimated GF Value™ of ₹4,514.26.
GuruFocus considers Sun Pharma Advanced Research Co to be Possible Value Trap.
Key valuation signals for NSE:SPARC:
Return-on-Tangible-Equity: 555.86%
GF Value™: ₹4,514.26 vs. price of ₹266.34 (94.1% below fair value)
Industry Position: 6936.2% above the Drug Manufacturers median (#49 of 897)
No single metric tells the full story. See the NSE:SPARC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sun Pharma Advanced Research Co Business Description
Sun Pharma Advanced Research Co Ltd is an Indian specialty and generic drug manufacturing company. The company has identified pharmaceuticals research and development as its only reportable segment. The company is focused on drug discovery in focused therapy areas such as cancer and anti-inflammatory treatments. The company considers merger and acquisition investment as a potential component of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities. It derives maximum revenue from India and also has its presence in other countries.
67GF Score
Get the complete analysis for NSE:SPARC
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SPARC has been successfully added to your 
